Sorrento Therapeutics, Inc. (SRNE)
| Market Cap | 163.11K -96.7% |
| Revenue (ttm) | 64.27M +16.9% |
| Net Income | -548.00M |
| EPS | -1.08 |
| Shares Out | 543.71M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 203,787 |
| Open | 0.0003 |
| Previous Close | 0.0003 |
| Day's Range | 0.0003 - 0.0004 |
| 52-Week Range | 0.000001 - 0.0100 |
| Beta | 0.11 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | n/a |
About Sorrento Therapeutics
Sorrento Therapeutics, Inc., a clinical and commercial stage biopharmaceutical company, provides therapeutic solutions in the United States and internationally. It offers chimeric antigen receptor T-cell therapy, dimeric antigen receptor T-cell therapy, and antibody-drug conjugates, as well as Seprehvec, SOFUSA, RTX, and SEMDEXA. The company also develops antiviral therapies and vaccines, including Abivertinib, COVI-MSC, COVI-AMG, COVIDROPS, and COVI SHIELD; and diagnostic test solutions, such as COVISTIX, COVITRACK, and Virex. Its products are... [Read more]
News
Sorrento Voyage Announces Expanded Luxury Boat Tours and Proposal Experiences Along the Amalfi Coast
Sorrento Voyage has announced the expansion of its private boat tours and romantic proposal experiences across the Amalfi Coast and Capri, offering travelers personalized sea-based journeys led by its...
DSI Introduces Westbury Sorrento Aluminum Railing with Bold Distinctive Mesh Stainless Steel Infills
Bremen, Indiana--(Newsfile Corp. - October 24, 2024) - Digger Specialties Inc. (DSI), a leading manufacturer of outdoor living products, is pleased to announce the addition of a 3-5/8" mesh infill opt...
Sorrento Resources Announces Appointment of Alex Bugden as President and Chief Executive Officer
Vancouver, British Columbia--(Newsfile Corp. - September 3, 2024) - SORRENTO RESOURCES LTD. (CSE: SRS) (OTCQB: SRSLF) (the "Company") is pleased to announce that Mr.
Sorrento Resources to Sell Three Newfoundland Properties to Gold Hunter
Vancouver, British Columbia--(Newsfile Corp. - May 29, 2024) - SORRENTO RESOURCES LTD. (CSE: SRS) (OCTQB: SRSLF) (the "Company") is pleased to announce that it has entered into a purchase agreement da...
Sorrento Resources Announces Appointment of Alex Bugden as a Director and Qualified Person
Vancouver, British Columbia--(Newsfile Corp. - May 8, 2024) - SORRENTO RESOURCES LTD. (CSE: SRS) (OCTQB: SRSLF) (the "Company") is pleased to announce that Mr.
DSI Introduces Westbury(R) Sorrento Aluminum and Stainless Steel Mesh Railing
Bremen, Indiana--(Newsfile Corp. - May 1, 2024) - Digger Specialties Inc. (DSI), a leading manufacturer of outdoor living products, is pleased to announce the introduction of Westbury® Sorrento Mesh R...
Virpax Pharmaceuticals Announces Proposed Settlement of Litigation with Sorrento Therapeutics, Inc. and Scilex Pharmaceuticals, Inc.
BERWYN, Pa.--(BUSINESS WIRE)-- #pharma--Virpax Announces Proposed Settlement of Litigation with Sorrento Therapeutics, Inc. and Scilex Pharmaceuticals, Inc.
Sorrento Therapeutics, Inc. Announces Auction for Sale of Scilex Securities and Bankruptcy Court Approval of Stalking Horse Bid
SAN DIEGO , Aug. 8, 2023 /PRNewswire/ -- Sorrento Therapeutics, Inc. (OTC: SRNEQ, "Sorrento" or "the Debtor"), a biopharmaceutical company dedicated to the development of life-saving therapeutics to t...
Gold Hunter Resources Completes the Sale of Certain Properties to Sorrento Resources
Vancouver, British Columbia--(Newsfile Corp. - June 14, 2023) - Gold Hunter Resources Inc. (CSE: HUNT) ("Gold Hunter" or the "Company") is pleased to announce, further to its press release on June 6, ...
Gold Hunter Resources Inc. Sells a Portion of Its Newfoundland Projects to Sorrento Resources
Vancouver, British Columbia--(Newsfile Corp. - June 6, 2023) - Gold Hunter Resources Inc. (CSE: HUNT) ("Gold Hunter" or the "Company") is pleased to announce it has entered into a mineral property pur...
Shanghai Escugen Biotechnology Co., Ltd., a partner of Levena Biopharma, a Sorrento Company, releases positive results from a first-in-human study of ESG401, a TROP2 Antibody Drug Conjugate in patients with locally advanced/metastatic solid tumors at the
CHICAGO, June 05, 2023 (GLOBE NEWSWIRE) -- Shanghai Escugen Biotechnology Co., Ltd. (“Escugen”), a partner of Levena (Suzhou) Biopharma Co., Ltd. (“Levena”), a wholly owned subsidiary of Sorrento Ther...
Sorrento Therapeutics Annual report: H2 2022
Sorrento Therapeutics has published its H2 2022 annual report on March 16, 2023.
Sorrento Therapeutics approved for $75M in financing in chapter 11 case
Sorrento Therapeutics (SRNE) announced that the U.S. Bankruptcy Court for the Southern District of Texas granted interim approval of Sorrento’s $75M debtor-in-possession financing from JMB Capital Par...
Sorrento Therapeutics, Inc. Receives Court Approval for $75 Million Financing in Chapter 11 Case
SAN DIEGO , Feb. 21, 2023 /PRNewswire/ -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento"), a biopharmaceutical company dedicated to the development of life-saving therapeutics to treat cancer, ...
Sorrento Posts Form 8937 to Supplement its Previously Issued “FAQ” Regarding the Dividend of Scilex Holding Company Common Stock (Nasdaq: SCLX, “Scilex”)
SAN DIEGO, Feb. 18, 2023 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”) today posted an IRS Form 8937 (the “Form 8937”) to supplement its previously issued “Frequently Aske...
Sorrento Issues Update to its Previously Issued “FAQ” Regarding the Dividend of Scilex Holding Company Common Stock (Nasdaq: SCLX, “Scilex”)
SAN DIEGO, Feb. 17, 2023 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”) today posted an update to its previously issued “Frequently Asked Questions” document under the “Inv...
Sorrento Therapeutics, Inc. Receives Court Approval for "First Day" Employee Wages and Cash Management Motions
SAN DIEGO , Feb. 16, 2023 /PRNewswire/ -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento"), a biopharmaceutical company dedicated to the development of life-saving therapeutics to treat cancer, ...
Scilex says not a debtor in Sorrento’s voluntary Chapter 11 filing
Scilex Holding Company (SCLX), a majority-owned subsidiary of Sorrento Therapeutics (SRNE), together with Sorrento, issued the following statements. Henry Ji, Ph.D., Chairman and CEO of Sorrento, comm...
Joint Statement by Sorrento Therapeutics, Inc. and Scilex Holding Company on Today's Isolated Chapter 11 Filing By Sorrento Therapeutics, Inc.
SAN DIEGO and PALO ALTO, Calif., Feb. 13, 2023 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex”), a majority-owned subsidiary of Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”...
A biotech company that once claimed to have a 'cure' for COVID-19 just filed for bankruptcy, sending shares plunging 59%
A famed short-seller already had Sorrento Therapeutics in its sights as far back as 2020. That pressure came to a head Monday.
Sorrento Therapeutics downgraded to Neutral from Buy at Dawson James
Dawson James downgraded Sorrento Therapeutics to Neutral from Buy.
Sorrento Therapeutics files for Chapter 11 bankruptcy in Texas
Sorrento Therapeutics files for Chapter 11 bankruptcy protection in the Southern District of Texas, according to a regulatory filing. "To protect the Company’s business and maximize its value, on Febr...
Scilex Holding Company, a majority-owned subsidiary of Sorrento Therapeutics, Inc., acquires rights to FDA-Approved ELYXYB™ in the U.S. and Canada for the acute treatment of migraine
PALO ALTO, Calif., Feb. 12, 2023 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex”), a majority-owned subsidiary of Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”), an innovati...
Scilex Holding Company, a majority-owned subsidiary of Sorrento Therapeutics, Inc., Announces Record and Meeting Dates for its first Annual Meeting of Stockholders
PALO ALTO, Calif., Feb. 04, 2023 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex”), a majority-owned subsidiary of Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”), an innovati...
Sorrento Distributes Dividend Confirmation Statements to 146 Brokerage Firms and Provides Specific Instruction to Continental Stock Transfer & Trust Company Regarding the Dividend of Scilex Holding Company Common Stock
SAN DIEGO, Feb. 03, 2023 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”) today distributed dividend confirmation statements to 146 brokerage firms regarding its recent divid...